Point72 Asset Management L.P. Increases Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Point72 Asset Management L.P. increased its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 69.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 516,934 shares of the company's stock after buying an additional 211,805 shares during the quarter. Point72 Asset Management L.P. owned about 0.85% of Health Catalyst worth $4,208,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. First Light Asset Management LLC boosted its position in Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company's stock worth $25,279,000 after purchasing an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc boosted its position in Health Catalyst by 16.4% in the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company's stock worth $20,793,000 after purchasing an additional 360,201 shares in the last quarter. Millennium Management LLC boosted its position in Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company's stock worth $15,421,000 after purchasing an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA boosted its position in Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company's stock worth $19,572,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Daventry Group LP boosted its position in Health Catalyst by 3.9% in the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company's stock worth $14,359,000 after purchasing an additional 84,178 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Price Performance

NASDAQ HCAT traded up $0.05 during mid-day trading on Monday, hitting $8.40. The stock had a trading volume of 300,627 shares, compared to its average volume of 564,667. The firm's 50 day moving average is $8.13 and its 200 day moving average is $7.38. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market capitalization of $511.12 million, a price-to-earnings ratio of -6.34 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period in the prior year, the company posted ($0.22) earnings per share. The firm's revenue for the quarter was up 3.5% compared to the same quarter last year. Equities research analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

HCAT has been the topic of several recent research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Evercore ISI increased their target price on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Tuesday, October 8th. Piper Sandler reiterated an "overweight" rating and set a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Stephens increased their target price on Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a research report on Thursday, November 14th. Finally, Citigroup increased their target price on Health Catalyst from $9.00 to $10.50 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Health Catalyst presently has a consensus rating of "Moderate Buy" and an average target price of $11.79.

Insiders Place Their Bets

In related news, insider Kevin Lee Freeman sold 7,500 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the sale, the insider now directly owns 236,950 shares of the company's stock, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the firm's stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the sale, the chief operating officer now directly owns 134,899 shares of the company's stock, valued at $1,036,024.32. The trade was a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,566 shares of company stock valued at $169,130 in the last three months. 2.50% of the stock is currently owned by insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.